CoChat
Sign Up
Cited by 355Bone health and osteoporosis researchBone Metabolism and DiseasesEstrogen and related hormone effects

Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice

Open access
Lane, Nancy E, Yao, Wei, Balooch, Mehdi, Nalla, Ravi K, Balooch, Guive, Habelitz, Stefan, Kinney, John H, Bonewald, Lynda F·2006·Journal of Bone and Mineral Research
DOI 10.1359/jbmr.051103PMC PMC1797152
Open this paper in CoChat — free account

Abstract

UNLABELLED: This study compares changes in bone microstructure in 6-month-old male GC-treated and female ovariectomized mice to their respective controls. In addition to a reduction in trabecular bone volume, GC treatment reduced bone mineral and elastic modulus of bone adjacent to osteocytes that was not observed in control mice nor estrogen-deficient mice. These microstructural changes in combination with the macrostructural changes could amplify the bone fragility in this metabolic bone disease. INTRODUCTION: Patients with glucocorticoid (GC)-induced secondary osteoporosis tend to fracture at higher bone mineral densities than patients with postmenopausal osteoporosis. This suggests that GCs may alter bone material properties in addition to BMD and bone macrostructure. MATERIALS AND METHODS: Changes in trabecular bone structure, elastic modulus, and mineral to matrix ratio of the fifth lumbar vertebrae was assessed in prednisolone-treated mice and placebo-treated controls for comparison with estrogen-deficient mice and sham-operated controls. Compression testing of the third lumbar vertebrae was performed to assess whole bone strength. RESULTS: Significant reductions in trabecular bone volume and whole bone strength occurred in both prednisolone-treated and estrogen-deficient mice compared with controls after 21 days (p < 0.05). The average elastic modulus over the entire surface of each trabecula was similar in all the experimental groups. However, localized changes within the trabeculae in areas surrounding the osteocyte lacunae were observed only in the prednisolone-treated mice. The size of the osteocyte lacunae was increased, reduced elastic modulus around the lacunae was observed, and a "halo" of hypomineralized bone surrounding the lacunae was observed. This was associated with reduced (nearly 40%) mineral to matrix ratio determined by Raman microspectroscopy. These localized changes in elastic modulus and bone mineral to matrix ratio were not observed in the other three experimental groups. CONCLUSIONS: Based on these results, it seems that GCs may have direct effects on osteocytes, resulting in a modification of their microenvironment. These changes, including an enlargement of their lacunar space and the generation of a surrounding sphere of hypomineralized bone, seem to produce highly localized changes in bone material properties that may influence fracture risk.

Integrity signals

Registry

Crossref · 10.1359/jbmr.051103

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Prolonged glucocorticoid treatments worsen bone quality.

    “Prolonged GC treatments further worsen the bone quality [35, 55]”

    From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [35]

  • The adverse effect of glucocorticoids on cortical bone quality may not correlate with whole bone mass or bone mineral density.

    “This finding again suggests the adverse effect of GC on the cortical bone quality may not correlate with whole bone mass or bone mineral density [35, 59].”

    From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [35]

  • Compared to other studies on glucocorticoid-induced osteoporosis that used skeletal matured mice, glucocorticoid excess in young growing mice has more profound inhibition on periosteal expansion with similar degree of trabecular bone loss.

    “Compared to the other studies that we and others have published on GIOP that used skeletal matured mice, we found GC excess in the young growing have more profound inhibition on periosteal expansion with similar degree of trabecular bone loss [35, 41].”

    From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [35]

Cites

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F.
Affiliations
  • University of California, Davis (US)
  • Lawrence Berkeley National Laboratory (US)
  • University of California, San Francisco (US)
  • University of Missouri–Kansas City (US)
Corresponding author
Lane, Nancy E
ORCID
Venue
Journal of Bone and Mineral Research
Publisher
Oxford University Press (OUP)
Published
2006-03-01
Volume
21
Issue
3
Pages
466-476
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
DOI
10.1359/jbmr.051103
PMC
PMC1797152
OpenAlex
W2074016952
Cited by
355
References
47
Citations by year
2026: 5 · 2025: 11 · 2024: 11 · 2023: 13 · 2022: 16 · 2021: 17 · 2020: 22 · 2019: 21 · 2018: 20 · 2017: 16 · 2016: 15 · 2015: 26 · 2014: 13 · 2013: 17 · 2012: 21
FWCI
23.85
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Journal of Bone and Mineral Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5r01dk046661-05)
  • University of California, San Francisco
  • National Cancer Institute (P50CA095817)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK46661-10)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR043052, K24AR048841, 1-K24-AR-48841-02, P01AR046798, P01AR46798)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD046661)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords
glucocorticoid-induced osteoporosis, prednisolone, trabecular bone microarchitecture, bone material properties, elastic modulus, ovariectomy, estrogen deficiency, bone fragility, fracture risk, bone strength, lumbar vertebrae
MeSH terms
Animals, Bone and Bones, Elasticity, Estrogens, Glucocorticoids, Male, Mice, Inbred Strains, Osteocytes, Placebos, Prednisolone, Tomography, X-Ray Computed, Biomarkers, Bone Density, Bone Remodeling, Compressive Strength, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review